Posts by: Santiago Gisler

Santiago Gisler

May 22, 2019May 22, 2019

Naftopidil Inhibits Proliferation of Human Lung Fibroblasts and Reduces Lung Fibrosis in Mice, Study Finds

News

Naftopidil treatment causes growth arrest of human lung fibroblasts and reduces fibrotic lesions in mice with idiopathic pulmonary fibrosis (IPF), a study shows. The findings of the study, “Naftopidil ... Read more

May 15, 2019May 15, 2019

Patients with Fibrotic ILD Commonly Experience Loss of Workplace Productivity, Study Finds

News

Loss of productivity in the workplace is common among patients with fibrotic interstitial lung disease (ILD), and is associated with symptom severity and higher costs, according to data from ... Read more

April 24, 2019April 30, 2019

Indalo Therapeutics Starts Phase 1 Trial Testing Antifibrotic Candidate IDL-2965

News

Indalo Therapeutics has launched a Phase 1 clinical trial testing the company’s lead antifibrotic candidate IDL-2965 for patients with fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis ... Read more

April 22, 2019April 22, 2019

PFF Summit 2019 in Texas to Present the Latest Research Affecting the PF Community

News

The pulmonary fibrosis (PF) community is invited to attend the Pulmonary Fibrosis Foundation‘s PFF Summit, which is the largest healthcare meeting on PF, offering data on the latest research. ... Read more

April 12, 2019April 12, 2019

Phase 1 Trial Testing PLN-74809 Supports its Clinical Development for IPF Treatment, Pliant Announces

News

Pliant Therapeutics has successfully completed a Phase 1 clinical study assessing its investigational therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF), with results supporting further clinical development of the compound. ... Read more

April 9, 2019April 18, 2019

High Monocyte Levels Linked to Poorer Outcomes in IPF, Other Fibrotic Diseases, Study Finds

News

Blood levels of immune cells called monocytes may help predict disease severity and determine the risk of poor outcomes in patients with idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, ... Read more

April 5, 2019April 5, 2019

Veracyte’s Envisia Classifier Improves ILD/IPF Diagnosis, Study Says

News

Envisia Genomic Classifier — a non-invasive diagnostic test developed by Veracyte and used as a complement to high-resolution computed tomography (HRCT) imaging — improves diagnosis of interstitial lung disease (ILD) ... Read more

April 3, 2019April 3, 2019

Increased Honeycombing Areas a Prognostic Factor in IPF, Study Finds

News

Quantification of so-called honeycombing areas (patches of cystic spaces) in the lungs seen through high-resolution computed tomography (HRCT) may be a predictor of mortality in people with idiopathic pulmonary ... Read more

March 29, 2019May 15, 2019

Registration Open for Medical Centers with PF Expertise to Join PFF Care Center Network

News

The Pulmonary Fibrosis Foundation (PFF) has opened a new registration cycle for medical centers that wish to join the Foundation’s Care Center Network, with the mission of improving the healthcare ... Read more

March 19, 2019March 22, 2019

Study Finds Increased Risk of PF Among World Trade Center Responders

News

Exposure to dust in the aftermath of the World Trade Center attacks increased the risk of pulmonary fibrosis (PF) among responders, according to an evaluation of self-reported surveys. Researchers found ... Read more